| Literature DB >> 34870329 |
Rebecca Borella1, Sara De Biasi1, Annamaria Paolini1, Federica Boraldi2, Domenico Lo Tartaro1, Marco Mattioli1, Lucia Fidanza1, Anita Neroni1, Alfredo Caro-Maldonado3, Marianna Meschiari4, Erica Franceschini4, Daniela Quaglino2, Giovanni Guaraldi4,5, Carlo Bertoldi5, Marco Sita6, Stefano Busani5,6, Massimo Girardis5,6, Cristina Mussini4,5, Andrea Cossarizza1,7, Lara Gibellini1.
Abstract
To better understand the mechanisms at the basis of neutrophil functions during SARS-CoV-2, we studied patients with severe COVID-19 pneumonia. They had high blood proportion of degranulated neutrophils and elevated plasma levels of myeloperoxidase (MPO), elastase, and MPO-DNA complexes, which are typical markers of neutrophil extracellular traps (NET). Their neutrophils display dysfunctional mitochondria, defective oxidative burst, increased glycolysis, glycogen accumulation in the cytoplasm, and increase glycogenolysis. Hypoxia-inducible factor 1α (ΗΙF-1α) is stabilized in such cells, and it controls the level of glycogen phosphorylase L (PYGL), a key enzyme in glycogenolysis. Inhibiting PYGL abolishes the ability of neutrophils to produce NET. Patients displayed significant increases of plasma levels of molecules involved in the regulation of neutrophils' function including CCL2, CXCL10, CCL20, IL-18, IL-3, IL-6, G-CSF, GM-CSF, IFN-γ. Our data suggest that metabolic remodelling is vital for the formation of NET and for boosting neutrophil inflammatory response, thus, suggesting that modulating ΗΙF-1α or PYGL could represent a novel approach for innovative therapies.Entities:
Keywords: COVID-19; glycolysis; metabolism; neutrophil extracellular traps; neutrophils
Mesh:
Substances:
Year: 2021 PMID: 34870329 DOI: 10.1002/eji.202149481
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532